Wedbush reiterated their outperform rating on shares of Kinnate Biopharma (NASDAQ:KNTE – Get Rating) in a research report report published on Wednesday morning, MarketBeat Ratings reports. The firm currently has a $33.00 price objective on the stock.
Several other analysts have also recently issued reports on KNTE. Piper Sandler cut their price target on shares of Kinnate Biopharma from $52.00 to $30.00 and set an overweight rating on the stock in a report on Wednesday, May 18th. The Goldman Sachs Group cut their price target on shares of Kinnate Biopharma from $44.00 to $29.00 and set a buy rating on the stock in a report on Tuesday, May 24th. Finally, HC Wainwright began coverage on shares of Kinnate Biopharma in a report on Thursday, July 28th. They issued a buy rating and a $33.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Kinnate Biopharma has an average rating of Buy and a consensus price target of $34.33.
Kinnate Biopharma Price Performance
KNTE opened at $12.37 on Wednesday. The stock has a market capitalization of $546.09 million, a PE ratio of -5.15 and a beta of -0.30. The firm’s fifty day moving average price is $13.38 and its 200 day moving average price is $10.86. Kinnate Biopharma has a 12-month low of $7.18 and a 12-month high of $26.05.
Hedge Funds Weigh In On Kinnate Biopharma
Kinnate Biopharma Company Profile
Kinnate Biopharma Inc, a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.
- Get a free copy of the StockNews.com research report on Kinnate Biopharma (KNTE)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
Receive News & Ratings for Kinnate Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinnate Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.